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ABSTRACT
Purpose: Germ cell tumors (GCTs) are highly sensitive
to cisplatin-based chemotherapy. This feature is unex-
plained, as is the intrinsic chemotherapy resistance of ma-
ture teratomas and the resistant phenotype of a minority of
refractory GCTs. Various cellular pathways may influence
the efficacy of chemotherapy. Their impact has not been
investigated in a comprehensive study of tumor samples
from clinically defined subgroups of GCT patients.
Experimental Design: We investigated proteins involved
in regulation of apoptosis (p53, BAX, BCL-2, and BCL-XL),
cell cycle control [p21 and retinoblastoma protein (RB)], and
drug export and inactivation [P-glycoprotein, multidrug re-
sistance-associated protein (MRP) 1, MRP2, breast cancer
resistance protein, lung resistance protein, metallothionein,
and glutathione S-transferase ] immunohistochemically in
samples of unselected GCT patients (n  20), patients with
advanced metastatic disease in continuous remission after
first-line chemotherapy (n  12), and chemotherapy-refrac-
tory patients (n  24). Mature teratoma components (n 
10) within tumor samples from all groups were analyzed
separately. The apoptotic index was studied by terminal
deoxynucleotidyl transferase-mediated nick end labeling
assay.
Results: Invasive GCTs of all groups showed a correla-
tion between wild-type p53 and apoptotic index (rs  0.66;
P < 0.001). The levels of the antiapoptotic proteins BCL-2
and BCL-XL were generally low. p21 was hardly detectable
and did not correlate with p53 (rs  0.29; P  0.07). No
significant differences among the three patient groups were
identified regarding any of the investigated parameters (all
Ps were >0.08), even though only individual samples from
chemotherapy-resistant cases showed a strong staining for
MRP2 and GST. In contrast to other components, mature
teratomas showed an intense p21 and RB staining and were
mostly positive for MRP2, lung resistance protein, and
GST.
Conclusions: Our results indicate a multifactorial basis
for the chemosensitivity of GCTs with lack of transporters
for cisplatin, of antiapoptotic BCL-2 family members, of p21
induction by p53, and of RB and an intact apoptotic cascade
downstream of p53. These findings suggest a preference for
apoptosis over cell cycle arrest after up-regulation of p53.
None of the examined parameters offers a general explana-
tion for the chemotherapy-resistant phenotype of refractory
tumors. The up-regulation of various factors interfering
with chemotherapy efficacy and ability for a p21-induced
cell cycle arrest may explain the intrinsic chemotherapy
resistance of mature teratomas.
INTRODUCTION
GCTs,4 in particular those of the testis, are the most fre-
quent malignancy in males between 20 and 45 years of age (1).
Based on histological, biological, and clinical differences, GCTs
are divided into seminomas and nonseminomas. The nonsemi-
nomas can be composed of one or more of the following
elements: embryonal carcinoma; yolk sac tumor; choriocarci-
noma; mature teratoma; and immature teratoma. They can also
contain a seminoma component (2). Compared with the vast
majority of solid tumors of adults, GCTs are highly sensitive to
cytotoxic treatment. Even in metastatic stages, 80% of patients
can be cured by a CDDP-based multiagent chemotherapy fol-
lowed by secondary resection in case of residual tumor lesions,
which can contain pure necrosis, viable malignant cells, or
mature teratoma (3, 4). In contrast to the other histological
components, mature teratomas show a benign clinical behavior
but are unresponsive to chemotherapy. Mature teratomas need to
be surgically removed to avoid growing teratoma (5) or trans-
formation into a secondary non-germ cell malignancy (6).
About 10% of patients diagnosed with a GCT will be
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unresponsive to CDDP-based chemotherapy or will relapse and
subsequently develop progressive disease despite further treat-
ment. Even though several new drugs including paclitaxel,
oxaliplatin, and gemcitabine have shown some promise in this
setting (7–10), there is hardly a chance to cure patients suffering
from chemotherapy-resistant disease (11). The biological basis
for the differential behavior of GCTs to chemotherapy is un-
clear. It is generally assumed that the high curability reflects the
characteristics of primordial germ cells, which are the presumed
cells of origin (12), and the embryonal cell types derived from
them. These cells undergo apoptosis readily upon exposure to
external stress (13). We have recently demonstrated that the
mere level of wild-type p53 does not explain the chemosensi-
tivity of these tumors (14).
CDDP is considered the most important drug in the sys-
temic treatment of GCTs. CDDP exerts its action via induction
of apoptosis (15). The crucial damage inflicted by CDDP is
supposed to be covalent binding to DNA. The DNA damage has
to be detected to activate an apoptotic cascade leading to cell
death. Theoretically, resistance can occur at various levels in
this process (16): (a) the drug can be inactivated by reduction
with glutathione or metallothionein or exported out of the cell
by various transporter proteins, e.g., members of the ABC
transporters, before it can interact with DNA (17); (b) the
generated DNA damage may be repaired before it results in
activation of an apoptotic cascade, predominantly by the nuclear
excision repair pathway (18); and (c) the damage recognition or
execution of an apoptotic program can be impaired or blocked
by mutations/deletions of apoptotic effectors or overexpression
of antiapoptotic proteins (for example, members of the BCL-2
family). The common result of these different scenarios is
failure to undergo programmed cell death (16). Several expla-
nations for the chemosensitivity of GCTs such as impaired
up-regulation of GST (19), low DNA repair capacity (20), or
lack of antiapoptotic members of the BCL-2 family (21) have
been suggested. These models are predominantly based on in
vitro analyses of cell lines and lack confirmation of their rele-
vance in clinical material (22). We therefore investigated a
variety of putative resistance mechanisms in such clinical ma-
terial to seek an explanation for the exquisite chemosensitivity
of GCTs in general, the intrinsic resistance of mature teratomas,
and the potential occurrence of chemotherapy resistance in
GCTs.
MATERIALS AND METHODS
Patients and Tissue Samples. Tumor tissue from three
patient groups was investigated: (a) unselected patients with
GCTs containing all histological subtypes (n  20); (b) patients
with advanced metastatic nonseminomas achieving long-term
remissions after first-line CDDP-based chemotherapy (n  12);
and (c) clinically defined refractory patients (n 24). Due to the
difference in clinical behavior of mature teratomas, components
of this histology occurring in all of these groups (n  10) were
analyzed separately.
Formalin-fixed paraffin-embedded tissue blocks from the
20 unselected cases (8 seminomas and 12 nonseminomas con-
taining various histological subtypes) were collected between
1998 and 2001 in close collaboration with urologists and pa-
thologists in the southwestern part of the Netherlands. They
were retrieved from the archive of the Laboratory for Experi-
mental Patho-Oncology, Department of Pathology, Erasmus
Medical Center/Daniel. No data on the clinical course were
available for these patients. The 12 patients with advanced
metastatic disease were treated within a Phase I/II study of the
German Testicular Cancer Study Group evaluating a dose-
intensified first-line treatment strategy for patients with poor
prognostic features (23). All patients remain in complete remis-
sion or marker-negative partial remission for a minimum fol-
low-up of 1 year (range, 1–6 years). The chemotherapy-resistant
series consisted of 24 patients diagnosed between 1986 and
1998 and treated within various experimental chemotherapy
trials led by Tu¨bingen University (Tu¨bingen, Germany). Pa-
tients were considered refractory when progression or relapse of
the disease occurred despite adequate CDDP-based initial and
salvage treatment. The tumor samples were obtained either at
initial diagnosis (i.e., before chemotherapy; n  16) or by
resection of a metastatic lesion in relapse (n  8).
Baseline characteristics of the patients are given in Table 1.
Immunohistochemistry. Paraffin sections of 3 m were
mounted on adhesive slides, deparaffinized, and rehydrated.
Whenever necessary, antigen retrieval was performed by auto-
claving [120°C; 1.2 bar] in different buffers 0.01 M sodium
citrate (pH 6) or 0.001 M EDTA (pH 8)]. Biotin-labeled rabbit
antimouse, swine antirabbit, or rabbit antirat immunoglobulins
and a biotinylated horseradish peroxidase-streptavidin complex
(both from DAKO, Glostrup, Denmark) were subsequently
applied for 30 min at room temperature. Diaminobenzidine
(Sigma, Zwijndrecht, the Netherlands) was used as chromogen.
The antibodies for the ABC transporters were raised by R. S.
and G. L. S. and were previously shown to be specific (24, 25).
For the remaining targets, commercially available antibodies
were used. Table 2 specifies the primary antibodies, incubation
conditions, and the positive controls for each antibody. Omitting
the primary antibody was used as a negative control in each
case.
For ABC transporters, LRP, metallothionein, GST, RB,
BCL-2, and BCL-XL, a staining unequivocally visible under
low-power magnification in the correct localization in at least
10% of tumor cells was considered positive. For p53 and p21,
the fraction of tumor cells with an intense nuclear staining was
counted in five randomly selected high-power fields for each
case; for further analysis, the mean of positive cells from all
fields counted was used. Differences in the range of p53-
positive cells compared with a previous publication (14) are
caused by the use of a different detection system.
TUNEL Assay to Detect Apoptotic Cells. Paraffin sec-
tions of 3 m were mounted on adhesive slides, deparaffinized,
rehydrated, and digested in 0.5% pepsine (Sigma) in 0.02 M HCl
for 20 min at 37°C. Slides were rinsed in H2O and PBS. PBS
was carefully removed, and the reaction mixture containing 3 U
terminal deoxynucleotidyl transferase (Fermentas, St. Leon-Rot,
Germany), 0.5 M biotinylated dUTP (Roche Diagnostics,
Mannheim, Germany), and 5 terminal deoxynucleotidyl trans-
ferase buffer (Fermentas) in an end volume of 50 l was
applied, sealed with a coverslip, and incubated at 37°C for 1 h.
Slides were rinsed in PBS containing 0.1% Tween 20 (Sigma).
The incorporated biotin was visualized with a biotinylated
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horseradish peroxidase-streptavidin complex and diaminobenzi-
dine identical to the immunohistochemical stainings. A brown
staining of the nucleus/nuclear remnants was considered posi-
tive. The apoptotic index was evaluated by counting the fraction
of apoptotic cells in five high-power fields.
Statistical Analysis. The results of the responders and
nonresponders and of the unselected invasive tumors and the
mature teratomas were compared by 2 test for immunohisto-
chemical parameters other than p53, p21, and the apoptotic
index. A possible correlation between the apoptotic index and
the fraction of cells positive for p53 or p21, respectively, was
analyzed by Spearman rank correlation. Differences in the frac-
tion of p53- or p21-positive cells and apoptotic index between
mature teratomas and invasive nonseminomas and between the
different treatment response groups were analyzed by the
Kruskal-Wallis test. Differences were considered significant
when P was 0.05.
RESULTS
Markers of Drug Export and Inactivation in Invasive
GCTs and Mature Teratomas. The results of the immuno-
histochemical analysis are summarized in Table 3. Four ABC
transporters (Pgp, MRP1, MRP2, and BCRP) and the major
vault protein LRP were investigated. Pgp, MRP2, and LRP (Fig.
1A) were rarely detected in invasive components of any of the
groups. BCRP was demonstrated in the syncytiotrophoblastic
cells of choriocarcinomas, consistent with its reported expres-
sion in normal placenta (25). The majority of invasive tumors
stained positive for MRP1. No significant differences were
detected between responding and nonresponding patient groups
regarding any of the proteins analyzed. However, individual
patients of the chemotherapy-refractory group showed a staining
for MRP2 or LRP (3 of 24 and 1 of 23, respectively), whereas
this was never observed in the group of responding patients
Table 1 Baseline patient characteristics by patient group
Mature teratoma components occurring in tumor samples from patients of all groups (five in unselected, two in chemosensitive, and three in







Median age (range) (yrs) 32 (18–43) 29 (21–47) 29 (16–56)
Histology
Seminoma 8 1 1
Nonseminoma 12 11 23
Stage at initial diagnosis (according to UICC)a
I NA 0 2
II NA 0 6
III NA 12 16
Median follow-up (range) (mo) NA 33 (12–71) 35 (11–180)
Median relapse-free survival (range) (mo) NA N.R. 5 (0–150)
Response to initial systemic treatment
Complete remission NA 0 4
Partial remission, marker negative NA 12 9
Partial remission, marker positive NA 0 2
Progressive disease NA 0 4
Unknown NA 0 5
Median number of salvage regimen (range) NA 0 3 (1–7)
a UICC, Union Internationale Contre le Cancer.
Table 2 Details on primary antibodies used for immunohistochemical stainings
All incubations with the primary antibodies were done at room temperature for 2 h.





Pgp JSB1 Mouse Rik Scheper ACa sodium-citrate, 0.01 M (pH 6) 1:20 Liver Membranous
MRP1 MRP R1 Rat Rik Scheper AC sodium-citrate, 0.01 M (pH 6) 1:20 Lung cancer Membranous
MRP2 M2III5 Mouse Rik Scheper AC sodium-citrate, 0.01 M (pH 6) 1:20 Liver Membranous
BCRP BXP 21 Mouse Rik Scheper AC EDTA, 0.001 M (pH 8) 1:20 Placenta Membranous
LRP Clone LRP06 Mouse Neomarkers AC sodium-citrate 0.01 M (pH 6) 1:200 Breast cancer Cytoplasmic
GST Ab1 Rabbit Neomarkers 1:50 Liver Cytoplasmic
Met Clone E9 Mouse Neomarkers 1:50 Breast cancer Cytoplasmic
p53 Clone Do7 Mouse DAKO AC sodium-citrate 0.01 M (pH 6) 1:50 Colon cancer Nuclear
p21 Clone EA10 Mouse Oncogene Science AC sodium-citrate 0.01 M (pH 6) 1:75 Colon Nuclear
RB Clone IF8 Mouse Neomarkers AC EDTA 0.001 M (pH 8) 1:100 Colon Nuclear
BAX Clone 2D2 Mouse Neomarkers AC sodium-citrate 0.01 M (pH 6) 1:100 Tonsil Cytoplasmic
BCL-2 Clone 124 Mouse DAKO AC sodium-citrate 0.01 M (pH 6) 1:50 Tonsil Cytoplasmic
BCL-XL Clone 7D9 Mouse Neomarkers AC EDTA 0.001 M (pH 8) 1:100 Melanoma Cytoplasmic
a AC, autoclaving at 120°C/1.2 bar; Met, metallothioenen.
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(P  0.20 and P  0.68). Yolk sac components were the only
histological subtype showing MRP2 staining and lacking MRP1
staining. Besides the transporters, metallothionein and GST
were included as proteins associated with inactivation of CDDP
by detoxification. GST was demonstrated in 5 of the 24
samples of chemotherapy-refractory patients compared with
none in the responding cases. However, this difference did not
reach significance (P  0.13). Again, only yolk sac tumors
expressed GST protein. Metallothionein was detected in about
one-third of the invasive tumors regardless of treatment out-
come or histology.
Mature teratomas, both residual and nonresidual, differed
significanty from the other histological components in most of
the investigated markers. In contrast to the other histological
elements, Pgp, MRP2, BCRP, LRP (Fig. 1B), and GST
showed an intense staining in the majority of mature teratomas.
MRP1, which was demonstrated in most invasive tumors, was
seen only rarely in mature teratomas. Apart from metallothio-
nein, the observed differences between mature teratomas and the
tumors of the unselected group of patients differed significantly
using the 2 test (P  0.038 for BCRP, and P  0.001 for the
remaining parameters). Within the group of chemotherapy-
refractory patients, no parameters differentiated patients relaps-
ing after initial remission and those progressing under treatment.
Spontaneous Apoptosis and Effectors and Regulators of
Apoptosis. With p21, BAX, and the TUNEL assay to dem-
onstrate apoptotic cells, two competing downstream effects of
p53 (apoptosis versus cell cycle arrest) were assessed. Sixteen of
the chemotherapy-refractory cases were previously shown to
have wild-type p53 by single-strand conformational polymor-
phism (14); in the remaing cases, the quality of extracted DNA
or the amount of available tissue precluded mutation analysis.
The fraction of cells positive for p53 or p21 and the apoptotic
index did not differ between unselected, responding, and non-
responding patients (P  0.82, P  0.92, and P  0.08).
However, the fraction of p53-positive cells was correlated with
the apoptotic index (rs  0.66 and P  0.001 for all invasive
tumors together), but not with the percentage of p21-positive
cells (rs  0.26; P  0.16). Seminomas had a lower apoptotic
index and a lower number of p53-positive cells than nonsemi-
nomas. Within the group of nonseminomas, no differences
between the histological subtypes were detected for p53 or
apoptotic index. p21 was hardly detected in invasive tumors
with the exception of the syncytiotrophoblastic cells. RB was
demonstrated only in part of the yolk sac tumors and in syncy-
tiotrophoblastic cells of choriocarcinoma, irrespective of the
treatment outcome. A markedly increased BAX signal was
detected in up to one-third of apoptotic cells (Fig. 1C). BCL-2
and BCL-XL were scarcely seen in vital invasive components.
Analyzing mature teratomas, no significant correlations
between the fraction of p53-positive cells and the fraction of
p21-positive cells or apoptotic index were observed, possibly
due to the limited number of cases studied. Despite a higher
percentage of P53-positive cells (mean SD, 14% 9% versus
6  9.0%; P  0.005) and of P21-positive cells (16%  7%
versus 1% 3%; P 0.001), mature teratomas showed a lower
apoptotic index (2% 4% versus 4% 3%; P 0.04) than the
remaining components. Fig. 2 illustrates the correlation between
p53 and p21/apoptotic index for invasive components and ma-
ture teratomas.
DISCUSSION
The exquisite chemosensitivity of GCTs has been attrib-
uted to their propensity to rapidly undergo apoptosis upon
exposure to external stress. A high level of functional p53 has
commonly been regarded as the crucial determinant of this
disposition (26). However, we (14) have demonstrated previ-
ously that this notion is an oversimplification because p53 level
and status did not correlate with treatment outcome. The results
of the current study offer a different explanation for the chemo-
sensitivity of GCTs. The profile of the tumor cells favors effi-
cacy of chemotherapeutic substances, in particular of CDDP, on
multiple levels: neither LRP nor any of the investigated export
pumps with affinity for CDDP was found in high levels in
responding and unselected invasive tumors. GST, an enzyme
able to inactivate CDDP by conjugation to glutathione, was
hardly detected by immunohistochemistry. In accordance with
data on GCT-derived cell lines, metallothionein was detectable
in some of the samples, regardless of treatment outcome (19).
Thus, the presence of metallothionein is not sufficient to confer
resistance to GCTs. Further contributing to the chemosensitiv-
ity, it has previously been shown that the repair of CDDP-
induced DNA damage may be impaired in GCTs (20). The
Table 3 Summary of immunohistochemical results
Fraction of tumors scored positive by evaluable tumors (percentage of tumors scored positive). Column A gives the P for the difference between
unselected tumors and the mature teratomas. Column B gives the P for the difference between responding and nonresponding tumors as determined
by 2 test. Statistically significant values are indicated in bold.
Antigen Unselected tumors Refractory tumors Responding tumors Mature teratomas A B
RB 4/20 (20%) 9/22 (41%) 3/12 (25%) 9/10 (90%) <0.001 0.354
BCL-2 3/20 (15%) 0/24 (0%) 1/12 (8%) 3/10 (30%) 0.333 0.151
BCL-XL 2/20 (10%) 7/23 (30%) 5/12 (42%) 10/10 (100%) <0.001 0.632
Pgp 0/20 (0%) 1/22 (5%) 0/12 (0%) 10/10 (100%) <0.001 0.453
MRP1 19/20 (95%) 15/23 (65%) 10/11 (91%) 2/9 (22%) <0.001 0.112
MRP2 0/17 (0%) 3/24 (13%) 0/12 (0%) 7/10 (70%) <0.001 0.201
BCRP 6/20 (30%) 5/22 (23%) 2/12 (17%) 7/10 (70%) 0.037 0.676
LRP 2/20 (10%) 1/23 (4%) 0/12 (0%) 8/10 (80%) <0.001 0.464
GST 0/17 (0%) 5/24 (21%) 0/12 (0%) 10/10 (100%) <0.001 0.125
Met 7/20 (35%) 10/22 (45%) 7/12 (58%) 2/10 (20%) 0.398 0.473
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current investigation did not include any parameter in this
regard.
Various parameters were analyzed to assess the down-
stream effects of p53 and regulators of apoptosis of the BCL-2
family in GCTs. The presence of high numbers of spontaneously
apoptotic cells, the correlation with p53 positivity, and the
presence of BAX in apoptotic cells suggest that the apoptotic
cascade of the p53-dependent mitochondrial pathway is intact
and activated in spontaneous apoptosis in untreated invasive
GCTs. None of the investigated antiapoptotic members of the
BCL-2 family was detected at high levels. In line with these
findings, a high ratio of BAX:BCL2 has previously been pro-
posed as a possible explanation for the sensitivity of GCT-
derived cell lines to etoposide (21). However, it is important to
note that it has not been demonstrated thus far which apoptotic
pathway is used by the tumor cells in response to treatment with
CDDP. The low level of p21 and the lack of correlation between
wild-type p53 and p21 suggest that GCT cells do not go into a
G1-S-phase arrest upon induction of p53, at least in the untreated
situation (27). The absence of RB in invasive tumors, confirmed
in this study, provides an additional argument for this assump-
tion (28, 29). It has previously been proposed that a defect in the
G1-S-phase cell cycle check point represents a crucial step in the
progression from preinvasive to invasive stages of GCTs (28).
However, the demonstration of both p21 and RB in residual and
nonresidual mature teratomas and in the syncytiotrophoblastic
cells of choriocarcinomas argues against an acquired defect in
cell cycle control on the level of p21 or RB expression. In our
opinion, the differential expression of these proteins reflects a
differentiation-dependent preference for G1-S-phase arrest in
(terminally differentiated) syncytiotrophoblasts and mature ter-
atoma cells, which is not found in the tumor cells that contain
embryonic characteristics. The p53 levels found in the invasive
tumors probably represent a response of the tumor cells to
external stress such as hypoxia, malnutrition, or changes in the
microenvironment rather than high intrinsic levels of p53. Thus,
induction of apoptosis by CDDP is supported by multiple in-
trinsic features of the tumor cells with embryonic characteristics
rather than by a single characteristic, such as a high level of p53.
The next objective of the study was to seek explanations
for the rare but clinically important occurrence of chemotherapy
resistance of invasive GCTs. No significant differences were
observed between the samples of patients with responding or
chemotherapy-refractory tumors in any of the parameters ana-
lyzed. Adding to our previous findings on p53, the identical
behavior regarding the correlation between p53 positivity and
apoptosis indicates that alterations of the p53-dependent mito-
chondrial apoptotic pathway are not a common means to
achieve treatment resistance in GCTs. This finding allows two
conclusions. (a) The CDDP-induced apoptosis could be exe-
cuted via a different pathway than spontaneous apoptosis, pos-
sibly not depending on functional p53 in the same way. Sup-
porting this hypothesis, we have recently detected a high
incidence of microsatellite instability in refractory GCTs (30).
Microsatellite instability is a consequence of a defect in the
DNA mismatch repair pathway. It has been proposed, that this
particular pathway is involved in induction of apoptosis on
recognition of DNA damage (31). Interestingly, inactivation of
p53 in cell lines with a defective MMR resulted in hypersensi-
tivity toward CDDP in various models (Ref. 32 and the refer-
ences cited therein). (b) Resistance in GCTs could be related to
factors acting upstream of p53. The presence of GST, LRP,
and MRP2 in some chemotherapy-refractory tumors might for
example explain the chemotherapy-resistant phenotype in these
cases. Due to the small numbers of tumors positive for either
LRP or MRP2, it is obvious that overexpression of these pro-
teins is not a common mechanism of resistance. However, it
might contribute to the chemotherapy-resistant phenotype in
Fig. 1 Representative examples of immunohistochemical stainings. Representative examples of immunohistochemical stainings are shown: A, LRP
staining in an embryonal carcinoma (note the absence of LRP in tumor cells); B, LRP staining in a mature teratoma; and C, apoptotic tumor cell
showing staining for BAX.
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selected cases, as has been postulated for GST in GCT-derived
cell lines (19).
In contrast to the other histological elements of GCTs, the
mature teratomas, both residual and nonresidual, are intrinsi-
cally resistant to chemotherapy (4). The three ABC transporters,
P-glycoprotein, MRP2, and BCRP, are present in this type of
tissue, and the latter two are supposed to have a role in CDDP
export (17). Whereas P-glycoprotein and MRP1 have been
analyzed in GCTs (33), to our knowledge, MRP2 and BCRP
have not been investigated in this context thus far. Drug export
by the ABC transporters might be further facilitated in mature
teratomas by conjugation of CDDP with glutathione because
GST was demonstrated as well. Similarly, the major vault
protein LRP, which has been correlated with the response of
small cell lung cancer and ovarian cancer to CDDP (34, 35), is
regularly detected in mature teratomas. On the level of apoptosis
and cell cycle control, additional differences were observed. As
indicated above, mature teratomas show immunohistochemi-
cally detectable levels of p21 and RB. It is therefore likely that
the tumor cells of mature teratoma can arrest at G1-S, i.e., they
have an intact G1-S checkpoint control. This might allow DNA
damage repair to occur, instead of apoptotic cell death. Finally,
the antiapoptotic BCL-2 was detected in mature teratomas.
Similar to the proposed multifactorial explanation for the gen-
eral chemosensitivity of invasive GCTs, the resistance of mature
teratomas seems to be determined on multiple levels, overall
with features opposite to those of the other GCT components.
Most likely, the chemotherapy-resistant phenotype is a conse-
quence of loss of embryonic features and gain of complete
somatic differentiation. Accordingly, the mature teratoma cells
should be as sensitive/resistant as nontumorous, differentiated
cells of the body. Therefore, doses of chemotherapy needed to
eliminate mature teratoma would be associated with unaccept-
able toxicity. Thus, complete surgical removal will probably
remain the appropriate intervention to handle these lesions.
The current study is based on immunohistochemical as-
sessment of potential regulators of chemotherapy sensitivity in
GCTs. Multiple caveats have to be kept in mind regarding
immunohistochemical studies, such as the effect of pretreatment
and tissue preservation. A “negative” finding might be due to a
concentration of the investigated target just below the detection
threshold of the method applied, rather than the complete ab-
sence of the protein. Accordingly, the results have been inter-
preted primarily comparing different histological elements of
GCTs and clinically defined subgroups rather than in absolute
terms. Therefore, the presented data provide valuable informa-
tion and suggest new concepts to understand the differential
behavior of subgroups of GCTs to chemotherapy.
In summary, the chemotherapy-refractory phenotype in
invasive GCTs is unlikely to be caused by aberrations in the
apoptotic pathway downstream of p53. Although it does not
explain all chemotherapy-refractory GCTs, overexpression of
GST, MRP, or LRP might confer resistance in individual
cases. The unique treatment sensitivity of most GCTs is prob-
ably a consequence of a cellular profile supporting optimal
efficacy of CDDP in particular on multiple levels. Mature ter-
atomas differ from this profile on each of these levels, most
likely reflecting their loss of embryonic features. The intrinsic
resistance of mature teratomas to chemotherapy is probably the
consequence of presence of a whole spectrum of resistance
markers from drug export to cell cycle control.
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(Department of Pathology/Laboratory for Experimental Patho-Oncol-
ogy, Erasmus Medical Center/Daniel) for helpful discussions.
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